Peripheral T Cell Lymphoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Recruiting
- Hodgkin Lymphoma
- +2 more
- brentuximab vedotin
- Anaheim, California
- +18 more
2022-04-01
Apr 1, 2022A
Active, not recruiting
- Peripheral T Cell Lymphoma
- Transformed Mycosis Fungoides
- Birmingham, Alabama
- +68 more
2022-03-28
Mar 28, 2022S
Recruiting
- Hodgkin Disease
- Peripheral T Cell Lymphoma
- brentuximab vedotin
- +3 more
- Birmingham, Alabama
- +53 more
2022-03-18
Mar 18, 2022S
Not yet recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
- (no location specified)
2022-03-18
Mar 18, 2022U
Recruiting
- Peripheral T Cell Lymphoma
- ATLCAR.CD30 T cells
- +3 more
- Chapel Hill, North Carolina
- +1 more
2022-03-04
Mar 4, 2022S
Not yet recruiting
- Peripheral T Cell Lymphoma
- +3 more
- STI-3031
- (no location specified)
2022-03-14
Mar 14, 2022N
Recruiting
- Non Hodgkin Lymphoma
- +2 more
- Hefei, Anhui, China
- +2 more
2022-02-25
Feb 25, 2022U
Active, not recruiting
- Peripheral T Cell Lymphoma
- Nivolumab and EPOCH
- Duarte, California
- +2 more
2022-02-03
Feb 3, 2022W
Active, not recruiting
- Peripheral T Cell Lymphoma
- Tumor biopsy
- +2 more
- Boston, Massachusetts
- +2 more
2022-02-14
Feb 14, 2022R
Not yet recruiting
- Peripheral T Cell Lymphoma
- (no location specified)
2022-02-04
Feb 4, 2022T
Active, not recruiting
- Lymphoma, Large B-Cell, Diffuse
- +3 more
- Nanjing, Jiangsu, ChinaHematological Department, People's Hospital of Jiangsu Province
2021-12-30
Dec 30, 2021T
Recruiting
- Peripheral T Cell Lymphoma
- Relapse/Recurrence
- Lacutamab
- +2 more
- Antwerpen, Belgium
- +38 more
2021-12-06
Dec 6, 2021B
Recruiting
- Diffuse Large B Cell Lymphoma
- +7 more
- BR101801 (Phase Ia)
- +2 more
- Seoul, Korea, Republic of
- +2 more
2021-11-19
Nov 19, 2021T
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
- Tokyo, JapanTakeda Selected Site
2021-09-29
Sep 29, 2021T
Recruiting
- Anaplastic Large Cell Lymphoma
- +4 more
- Duarte, California
- +3 more
2021-10-04
Oct 4, 2021U
Active, not recruiting
- Peripheral T Cell Lymphoma
- Birmingham, United Kingdom
- +12 more
2021-10-01
Oct 1, 2021R
Active, not recruiting
- Peripheral T Cell Lymphoma
- Ann Arbor, Michigan
- +2 more
2021-08-13
Aug 13, 2021N
Recruiting
- NK-Cell Lymphoma
- +2 more
- Methotrexate
- +9 more
- San Francisco, California
- +1 more
2021-09-01
Sep 1, 2021C
Recruiting
- Treatment-naïve
- Peripheral T Cell Lymphoma
- Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
- Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
- Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
2021-07-26
Jul 26, 2021B
Completed
- Peripheral T Cell Lymphoma
- +18 more
- Lake Success, New York
- +33 more
2021-07-05
Jul 5, 2021D
Recruiting
- Cutaneous T Cell Lymphoma
- Peripheral T Cell Lymphoma
- Microdevices
- +2 more
- Boston, MassachusettsDana Farber Cancer Institute
2021-06-22
Jun 22, 2021S
Recruiting
- Peripheral T Cell Lymphoma
- +4 more
- anti-TRBC1 CAR-T cell therapy
- Shanghai, Shanghai, ChinaXianmin Song
2021-03-31
Mar 31, 2021G
Recruiting
- Peripheral T Cell Lymphoma
- GB226
- Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
2021-03-02
Mar 2, 2021C
Not yet recruiting
- Peripheral T Cell Lymphoma
- Mitoxantrone Hydrochloride Liposome Injection
- Chidamide
- Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
2020-12-11
Dec 11, 2020P
Recruiting
- Peripheral T Cell Lymphoma
- Transplant, Autologous
- Beijing, ChinaBeijing Cancer Hospital
2020-12-02
Dec 2, 2020